Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Swabplus, L.P.
483
•Swabplus, L.P.•August 1, 2023

Swabplus, L.P. – FDA 483, Aug 1, 2023

Record Details

During an FDA inspection conducted from July 25 to August 1, 2023, at Swabplus, L.P., a contract repacker located in Rancho Cucamonga, CA, several critical observations were made. The inspection revealed significant compliance issues under the regulatory framework governing drug manufacturing practices.

Key violations included the failure to adhere to procedures preventing objectionable microorganisms in non-sterile drug products. Specifically, the firm did not perform required sanitization of its purified water system as per its own standard operating procedures (SOP0810.1). This was noted as a repeat observation, indicating a recurring compliance issue.

Additionally, the firm lacked appropriate controls over computer systems to ensure that changes to production and control records were made only by authorized personnel. The audit trails for analytical instruments like HPLC and FT-IR were not reviewed comprehensively, potentially allowing unauthorized retesting of samples.

Another significant issue was the labeling of drug products with expiration dates that exceeded those supported by stability data, as evidenced by discrepancies in the expiration dates of Dr. Piercing’s Aftercare products.

Further, the quality control unit's responsibilities and procedures were neither adequately documented nor followed. This included the absence of active SOPs for handling deviations from GMP laboratory procedures and inadequate document control measures, leading to potential unauthorized modifications.

The FDA requires Swabplus, L.P. to address these violations by implementing corrective actions, including revising SOPs, enhancing document control, and ensuring comprehensive review and authorization processes for all quality-related records. Failure to comply may result in further regulatory actions.

Company
Swabplus, L.P.
Inspection date
August 1, 2023
Product type
Drugs
Office
Los Angeles District Office
Person
  • Christopher R. Czajka (Consumer Safety Officer (Inspector))
View Company Profile

ID · 3d12f5d0-b45a-4b21-89e6-e817790270b0

Violation Codes1
21 CFR 211.192

Full citation text and observation details available on the Dashboard.

Other documents for Swabplus, L.P.
  • 483 - 2021-10-15October 15, 2021
  • WARNING_LETTER - 2019-04-11April 11, 2019
  • 483 - 2019-04-11April 11, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Swabplus, L.P.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.